

---

## List of Contents

|   |   |
|---|---|
| Protein Kinase Inhibitors for the Treatment of Disease:<br>The Promise and the Problems . . . . . | 1 |
| <i>P. Cohen</i>   |   |

### Part I. General Aspects of PKs Inhibition

|   |    |
|---|----|
| New Design Strategies for Ligands That Target Protein Kinase-Mediated<br>Protein-Protein Interactions . . . . . | 11 |
| <i>D.S. Lawrence</i>  |    |

### Part II. Pharmacological Potential and Inhibitors of Individual Classes of Protein Kinases

|   |     |
|---|-----|
| The Paullones: A Family of Pharmacological Inhibitors<br>of Cyclin-Dependent Kinases and Glycogen Synthase Kinase 3 . . . . . | 47  |
| <i>L. Meijer, M. Leost, O. Lozach, S. Schmitt, C. Kunick</i>  |     |
| Pharmacological Potential of p38 MAPK Inhibitors . . . . .  | 65  |
| <i>S. Kumar, S.M. Blake</i>   |     |
| Inhibitors of PKA and Related Protein Kinases . . . . .   | 85  |
| <i>M. Gäßel, C. Breitenlechner, S. Herrero, R. Engh, D. Bossemeyer</i>  |     |
| Inhibitors of Protein Kinase CK2: Structural Aspects . . . . .  | 125 |
| <i>R. Battistutta, S. Sarno, G. Zanotti</i>   |     |
| Aminoglycoside Kinases and Antibiotic Resistance. . . . .   | 157 |
| <i>D.H. Fong, D.L. Burk, A.M. Berghuis</i>  |     |

### Part III. Pharmacological Potential and Inhibitors of Individual Classes of Protein Phosphatases

|  |     |
|--|-----|
| Protein Tyrosine Phosphatases as Therapeutic Targets . . . . . | 191 |
| <i>A. Cheng, N. Uetani, C. Lampron, M.L. Tremblay</i>          |     |

---

|   |            |
|---|------------|
| Structure-Based Design of Protein Tyrosine Phosphatase Inhibitors . . . . .   | 215        |
| <i>N.P.H. Møller, H.S. Andersen, C.B. Jeppesen, L.F. Iversen</i>  |            |
| Biological Validation of the CD45 Tyrosine Phosphatase<br>as a Pharmaceutical Target . . . . .  | 263        |
| <i>D.R. Alexander</i>   |            |
| Serine/Threonine Protein Phosphatase Inhibitors with Antitumor Activity . .   | 295        |
| <i>R.E. Honkanen</i>  |            |
| <b>Part IV. Inhibitors in Clinical Use or Advanced Clinical Trials</b>  |            |
| Clinical Immunosuppression using the Calcineurin-Inhibitors Cyclosporin<br>and Tacrolimus . . . . .   | 321        |
| <i>N.R. Banner, H. Lyster, M.H. Yacoub</i>  |            |
| Targeted Therapy with Imatinib: An Exception or a Rule? . . . . .   | 361        |
| <i>D. Fabbro, G. Fendrich, V. Guez, T. Meyer, P. Furet, J. Mestan,<br/>J.D. Griffin, P.W. Manley, S.W. Cowan-Jacob</i>                                  |            |
| Clinical Aspects of Imatinib Therapy . . . . .  | 391        |
| <i>B.J. Druker</i>  |            |
| Isoquinolinesulfonamide: A Specific Inhibitor of Rho-Kinase<br>and the Clinical Aspect of Anti-Rho-Kinase Therapy . . . . .                             | 411        |
| <i>H. Hidaka, Y. Suzuki, M. Shibuya, Y. Sasaki</i>  |            |
| Discovery and Development of Iressa:<br>The First in a New Class of Drugs Targeted at the<br>Epidermal Growth Factor Receptor Tyrosine Kinase . . . . . | 433        |
| <i>A.E. Wakeling</i>  |            |
| <b>Subject Index . . . . .</b>  | <b>451</b> |